Market Forecast By Types (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine), By Applications (Diagnostic Applications, Therapeutic Applications), By Procedural Volume Assessment (Diagnostic Procedures, Therapeutic Procedures), By Source (Nuclear Reactors, Cyclotrons), By End-users (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, Others) And Competitive Landscape
| Product Code: ETC088662 | Publication Date: Jun 2021 | Updated Date: Jun 2026 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The South Korea Radiopharmaceutical Market was estimated at USD 407 Million in 2025 and is projected to reach USD 535 Million by 2032, growing at a CAGR of 4.0% from 2026 to 2032. This trajectory is driven by a growing aging population, increased incidences of cancer, and heightened investments in advanced nuclear medicine technologies. Additionally, the robust development of healthcare infrastructure, along with rising demand for precise diagnostic and therapeutic procedures, is expected to fuel market growth.
The South Korean radiopharmaceutical market has displayed stable, yet gradually decelerating growth, with rates of 5.0% in 2021 and 4.8% in 2022, tapering to 4.6% in 2023 and 2024. This trend is mainly attributed to consistent investments in advanced nuclear medicine technology, alongside rising consumer demand for precision diagnostics in oncology. The market is expected to reach a growth rate of 4.9% by 2029 and 4.8% in 2032, showcasing resilience amidst fluctuating healthcare priorities and regulatory frameworks. Enhancements in distribution infrastructure and a focus on sustainable energy solutions also play a vital role in supporting this sector's performance, ensuring a robust response to evolving healthcare challenges.
This graph highlights how the South Korea Radiopharmaceutical Market has steadily grown over the past five years, supported by major growth factors.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate | Major Drivers |
| 2021 | 5.0% | Improved nuclear medicine facilities boosted radiopharmaceutical production capacities |
| 2022 | 4.8% | Modernized radiopharmaceutical manufacturing facilities boost production efficiency significantly |
| 2023 | 4.6% | Manufacturing investments in advanced radiopharmaceutical facilities drive capacity growth |
| 2024 | 4.5% | New radiopharmaceutical manufacturing facilities boost production capacity utilization |
| 2025 | 4.6% | Health sector investments boost radiopharmaceutical production capacity in facilities |
| 2026 | 4.5% | Domestic radiopharmaceutical manufacturing investments boost supply chain resilience |
| 2027 | 4.6% | Strengthened nuclear medicine usage boosted radiopharmaceutical production capacity |
| 2028 | 4.4% | Domestic radiopharmaceutical manufacturers boost capacity through advanced equipment investments |
| 2029 | 4.9% | Radiopharmaceutical manufacturing automation boosts production efficiency and capacity |
| 2030 | 4.9% | State funded research initiatives boost domestic radiopharmaceutical manufacturing capabilities |
| 2031 | 4.7% | Increased production of radioisotopes boosted local healthcare supply chains |
| 2032 | 4.8% | Improved radiation therapy technologies increased demand for isotope production |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch’s advanced forecasting approach, validated with industry datasets as of June 2026.
Recent momentum in the South Korea Radiopharmaceutical Market has been characterized by significant advancements in imaging technologies and expanding applications in cancer treatment. Looking forward, the market is poised for a transformative phase, as innovations in radiopharmaceutical compounds and an emphasis on personalized medicine reshape the landscape.
While the market is experiencing healthy growth, challenges related to regulatory hurdles and the high costs associated with research and development remain prevalent. Nevertheless, the commitment to enhancing patient care through innovative radiopharmaceutical solutions signifies a promising outlook for stakeholders.
Several factors pose constraints to the growth of the South Korea Radiopharmaceutical Market. High production costs associated with radiopharmaceuticals can limit accessibility and affordability for healthcare providers and patients alike. Moreover, the regulatory landscape surrounding the approval and commercialization of new radiopharmaceutical agents can be complex and time-consuming, potentially delaying product availability. Additionally, the need for specialized handling and storage of radiopharmaceuticals may deter smaller healthcare facilities from integrating these technologies into their practice.
The South Korea Radiopharmaceutical Market is witnessing notable trends such as a shift towards targeted therapies that utilize radiopharmaceuticals for more effective treatment of malignancies. Furthermore, there is an increasing integration of artificial intelligence and machine learning technologies in diagnostic imaging, which enhances precision in patient outcomes. The rise of outpatient imaging services also signifies a change in patient care dynamics, promoting the use of radiopharmaceuticals in more accessible settings.
The opportunities within the South Korea Radiopharmaceutical Market are abundant, particularly in expanding applications in therapeutic areas beyond oncology. Innovations in radiolabeled compounds for cardiac and neurological disorders are gaining traction. Furthermore, ongoing research into novel radionuclide therapies presents significant potential for new product developments. Collaborations between academic institutions and industry stakeholders are set to yield ground-breaking advancements, providing lucrative investment avenues.
The South Korean government has actively supported the radiopharmaceutical sector through various initiatives aimed at boosting research and development. Programs aimed at enhancing the production capabilities of domestic radiopharmaceutical manufacturers have been introduced, alongside funding for innovative healthcare technologies. Regulatory bodies are also working to streamline approval processes, thereby facilitating quicker access to market for new products and improving overall patient care.
Looking ahead to the period of 2026-2032, the South Korea Radiopharmaceutical Market is set to experience transformative changes driven by continuous technological advancements and evolving healthcare needs. As more research uncovers novel applications for radiopharmaceuticals, particularly in personalized medicine, we can anticipate an expansion in treatment options available to clinicians. This evolution is likely to foster enhanced patient outcomes, making radiopharmaceuticals a cornerstone of modern medical practices in South Korea.
Recent developments in the South Korea Radiopharmaceutical Market indicate a growing trend towards the introduction of innovative diagnostic agents. Research initiatives are increasingly focusing on the development of hybrid imaging technologies that combine the strengths of different modalities, enhancing diagnostic capabilities. Additionally, collaborations between leading research institutions and healthcare providers are paving the way for clinical trials aimed at evaluating novel radiopharmaceuticals for a variety of therapeutic applications.
|
1 Executive Summary |
|
2 Introduction |
|
2.1 Key Highlights of the Report |
|
2.2 Report Description |
|
2.3 Market Scope & Segmentation |
|
2.4 Research Methodology |
|
2.5 Assumptions |
|
3 South Korea Radiopharmaceutical Market Overview |
|
3.1 South Korea Country Macro Economic Indicators |
|
3.2 South Korea Radiopharmaceutical Market Revenues & Volume, 2022 & 2032F |
|
3.3 South Korea Radiopharmaceutical Market - Industry Life Cycle |
|
3.4 South Korea Radiopharmaceutical Market - Porter's Five Forces |
|
3.5 South Korea Radiopharmaceutical Market Revenues & Volume Share, By Types, 2022 & 2032F |
|
3.6 South Korea Radiopharmaceutical Market Revenues & Volume Share, By Applications, 2022 & 2032F |
|
3.7 South Korea Radiopharmaceutical Market Revenues & Volume Share, By Procedural Volume Assessment, 2022 & 2032F |
|
3.8 South Korea Radiopharmaceutical Market Revenues & Volume Share, By Source, 2022 & 2032F |
|
3.9 South Korea Radiopharmaceutical Market Revenues & Volume Share, By End-users, 2022 & 2032F |
|
4 South Korea Radiopharmaceutical Market Dynamics |
|
4.1 Impact Analysis |
|
4.2 Market Drivers |
|
4.2.1 Increasing prevalence of cancer and cardiovascular diseases in South Korea |
|
4.2.2 Growing adoption of nuclear medicine for diagnosis and treatment |
|
4.2.3 Technological advancements in radiopharmaceuticals |
|
4.3 Market Restraints |
|
4.3.1 Stringent regulatory requirements for radiopharmaceutical production and distribution |
|
4.3.2 High costs associated with development and manufacturing of radiopharmaceuticals |
|
5 South Korea Radiopharmaceutical Market Trends |
|
6 South Korea Radiopharmaceutical Market, By Types |
|
6.1 South Korea Radiopharmaceutical Market, By Types |
|
6.1.1 Overview and Analysis |
|
6.1.2 South Korea Radiopharmaceutical Market Revenues & Volume, By Types, 2022-2032F |
|
6.1.3 South Korea Radiopharmaceutical Market Revenues & Volume, By Diagnostic Nuclear Medicine, 2022-2032F |
|
6.1.4 South Korea Radiopharmaceutical Market Revenues & Volume, By Therapeutic Nuclear Medicine, 2022-2032F |
|
6.2 South Korea Radiopharmaceutical Market, By Applications |
|
6.2.1 Overview and Analysis |
|
6.2.2 South Korea Radiopharmaceutical Market Revenues & Volume, By Diagnostic Applications, 2022-2032F |
|
6.2.3 South Korea Radiopharmaceutical Market Revenues & Volume, By Therapeutic Applications, 2022-2032F |
|
6.3 South Korea Radiopharmaceutical Market, By Procedural Volume Assessment |
|
6.3.1 Overview and Analysis |
|
6.3.2 South Korea Radiopharmaceutical Market Revenues & Volume, By Diagnostic Procedures, 2022-2032F |
|
6.3.3 South Korea Radiopharmaceutical Market Revenues & Volume, By Therapeutic Procedures, 2022-2032F |
|
6.4 South Korea Radiopharmaceutical Market, By Source |
|
6.4.1 Overview and Analysis |
|
6.4.2 South Korea Radiopharmaceutical Market Revenues & Volume, By Nuclear Reactors, 2022-2032F |
|
6.4.3 South Korea Radiopharmaceutical Market Revenues & Volume, By Cyclotrons, 2022-2032F |
|
6.5 South Korea Radiopharmaceutical Market, By End-users |
|
6.5.1 Overview and Analysis |
|
6.5.2 South Korea Radiopharmaceutical Market Revenues & Volume, By Hospitals, 2022-2032F |
|
6.5.3 South Korea Radiopharmaceutical Market Revenues & Volume, By Ambulatory Surgical Centers, 2022-2032F |
|
6.5.4 South Korea Radiopharmaceutical Market Revenues & Volume, By Diagnostic Centers, 2022-2032F |
|
6.5.5 South Korea Radiopharmaceutical Market Revenues & Volume, By Cancer Research Institutes, 2022-2032F |
|
6.5.6 South Korea Radiopharmaceutical Market Revenues & Volume, By Others, 2022-2032F |
|
7 South Korea Radiopharmaceutical Market Import-Export Trade Statistics |
|
7.1 South Korea Radiopharmaceutical Market Export to Major Countries |
|
7.2 South Korea Radiopharmaceutical Market Imports from Major Countries |
|
8 South Korea Radiopharmaceutical Market Key Performance Indicators |
8.1 Number of nuclear medicine procedures performed annually |
8.2 Investment in research and development for radiopharmaceuticals |
8.3 Adoption rate of new radiopharmaceutical technologies |
8.4 Number of partnerships or collaborations in the radiopharmaceutical industry |
8.5 Patient satisfaction and outcomes related to radiopharmaceutical usage |
|
9 South Korea Radiopharmaceutical Market - Opportunity Assessment |
|
9.1 South Korea Radiopharmaceutical Market Opportunity Assessment, By Types, 2022 & 2032F |
|
9.2 South Korea Radiopharmaceutical Market Opportunity Assessment, By Applications, 2022 & 2032F |
|
9.3 South Korea Radiopharmaceutical Market Opportunity Assessment, By Procedural Volume Assessment, 2022 & 2032F |
|
9.4 South Korea Radiopharmaceutical Market Opportunity Assessment, By Source, 2022 & 2032F |
|
9.5 South Korea Radiopharmaceutical Market Opportunity Assessment, By End-users, 2022 & 2032F |
|
10 South Korea Radiopharmaceutical Market - Competitive Landscape |
|
10.1 South Korea Radiopharmaceutical Market Revenue Share, By Companies, 2025 |
|
10.2 South Korea Radiopharmaceutical Market Competitive Benchmarking, By Operating and Technical Parameters |
|
11 Company Profiles |
|
12 Recommendations |
|
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here